Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,348
datasets available to search
ShareScore release 0.9.0
Dataset results
6,348 results for “Hepatitis”
Acute hepatitis B in Poland, 2010-2014 surveillance data
<p>The data file contains the raw data of the routine surveillance of acute hepatitis B in Poland, run by Sanitary Inspection and National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland. The dataset covers anonymized sociodemographic data, hepatitis markers test results and data on exposures on infection from acute HepB cases diagnosed and reported to surveillance system in Poland in 2010-2014.</p>
Raw data on the validation of the Polish language version of THE BRIEF HEPATITIS C KNOWLEDGE SCALE
<p>Raw data on the validation of the Polish language version of THE BRIEF HEPATITIS C KNOWLEDGE SCALE.</p>
MD simulation data: Intrinsic disorder is a conserved feature of hepatitis C virus E2 glycoprotein
<p><strong>Background</strong></p> <p>Equilibration, relaxation and production runs were performed on GPUs using the CUDA version of PMEMD in AMBER 16 and AMBER ff14SB force field. Minimisation steps were performed on a CPU using PMEMD in AMBER 16 and the AMBER ff14SB force field. The GLYCAM_06j-1 force field was used for the simulations of the glycosylated E2. All software is available from http://ambermd.org/. </p> <p><strong>Contents</strong></p> <p>There are three tarball (<strong>.tar.gz</strong>) files, one for each of the HCV strain investigated. </p> <p>The contents of each tarball is as follows:</p> <p>1. a source PDB (<strong>.pdb</strong>) file</p> <p>2. <strong>leap.scr</strong> - a script used to create the .prmtop and .inpcrd files</p> <p>3. Two AMBER parameter/topology (<strong>.prmtop</strong>) (one with hydrogen mass repartitioning) and an AMBER coordinate (<strong>.inpcrd</strong>) file </p> <p>4. Multiple control (<strong>.ctl</strong>) files numbered 1 to 10 that are used to minimize (<strong>min</strong> prefix), relax (<strong>rel</strong> prefix) and equilibrate (<strong>equ</strong> prefix) the model</p> <p>5. Executable <strong>do_md</strong> that performed all the minimisation, relaxation and equilibration steps</p> <p>6. File <strong>parmed.txt</strong> used to repartition the hydrogen atom mass (for the unglycosylated simulations)</p> <p>7. control file <strong>prod.ctl</strong> used for the production run </p> <p>8. Executable <strong>run_prod</strong> that was used to perform the production run</p> <p>9. Two control files (<strong>prod_short.ctl </strong>and <strong>prod_short_2.ctl</strong>) for the short runs used to de-correlate the simulation for the independent runs</p> <p>10. Executable <strong>run_short</strong> and <strong>run_short_2</strong> used to carry out the de-correlated production runs.</p> <p>10. Five AMBER trajectory (<strong>.nc</strong>) files for five independent MD simulations, numbered 1 to 5. <strong>Note: </strong>each of these files is over 2GB.</p>
Spleen STARmap PLUS dataset of Transient hepatic reconstitution of thymic factors enhances aged immunity
<p>Here is the STARmap PLUS dataset of Spleen section included in "<strong>Transient hepatic reconstitution of thymic factors enhances aged immunity</strong>" from Friedrich et al. </p>
Efficacy and in vitro pharmacological assessment of novel N-hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors
<p>The data here is summarized in Efficacy and in vitro pharmacological assessment of novel N-hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors by Woodson, et al. </p>
Data from: Population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area
<p><span><span><span><span><span><span><span><span><span><span><span><b>Background.</b> Data on the true prevalence of hepatitis C virus (HCV) infection in the </span></span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span><span><span>general population is essential to health policies. We evaluated a program implementing free universal HCV screening using a non-invasive point-of-care test (POCT) (OraQuick-HCV rapid test) in oral fluid in an urban area in Valencia, South-Eastern Spain. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods.</b> A cross-sectional study was performed during 2015-2017. Free HCV screening was offered by regular mail to 11,500 individuals aged 18 and over, randomly selected from all census residents in the Health Department. All responding participants filled in a questionnaire about HCV infection risk factors and were tested in their tertiary Hospital. In those with a positive POCT, results were confirmed by enzyme-immunoassay and HCV-RNA.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results.</b> 1,206 persons agreed to participate (response rate: 11.16%). HCV antibodies were detected in 19 (1.60%) cases (age-sex standardized rate: 1.31%; 95%CI: 0.82-2.07), but only 8 showed positive HCV-RNA (age-sex standardized rate: 0.56%; 95%CI: 0.28-1.14). The majority (89%) of the cases were born before 1965 and 74% had at least one known risk factor for HCV infection. All anti-HCV positive individuals were already aware of their infection, and no undiagnosed cases were detected. The performance of the POCT was excellent for detecting active infection. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions.</b> These preliminary data suggest that HCV population screening with a POCT is feasible but, in our setting, mailing recruiting is not effective (11% response rate). The low prevalence of HCV antibodies and active infection in the participant population (with no new diagnoses made) suggests that, in our setting, underdiagnosis may be uncommon.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Files uploaded include the study database (Stata v.13) and the do.file of the study.</b></span></span></span></span></span></span></span></span></span></span></span></p>
Neonatal exposure to BPA, BDE-99, and PCB produces persistent changes in hepatic transcriptome associated with gut dysbiosis in adult mouse livers
<p class="western"><span><span><span><b>Background</b>. Recent evidence suggests that multigenic and complex environmentally modulated diseases result from early life exposure to toxicants at least partly via gut microbial influences. Environmental toxicants, polybrominated diphenyl ethers (PBDEs), and polychlorinated biphenyls (PCBs) are breast milk-enriched persistent organic pollutants (POPs) and thus remain a continuing threat to human health despite being banned from production. Recent findings focused on the liver developmental reprogramming capabilities from neonatal BPA exposure; however, little is known on how PBDEs and PCBs regulate the liver transcriptome with respect to the gut microbiome. </span></span></span></p> <p class="western"><span><span><span><b>Objectives</b>. We investigated whether the gut microbiome can be persistently reprogrammed with the liver following neonatal exposure to POPs, and whether microbial biomarkers associated with disease-prone changes in the hepatic epigenetic and transcriptomic landscape in adulthood. </span></span></span></p> <p class="western"><span><span><span><b>Methods. </b>C57BL/6 male and female mouse pups were orally administered vehicle, bisphenol A (BPA), BDE-99 (a breast milk-enriched PBDE congener), or the Fox River PCB mixture (an environmentally relevant PCB mixture), between postnatal day (PND) 2 to 4, once daily for three consecutive days. Tissues were collected at PND5 and PND60 for 16S rDNA sequencing and targeted metabolomics.</span></span></span></p> <p class="western"><span><span><span><b>Results</b>. Neonatal exposure to BDE-99, followed by BPA and PCB, produced the greatest persistent changes in the adult hepatic transcriptome, including an inflammation and cancer-prone transcriptomic signature. BDE-99 exposure resulted in a persistent increase in <i>Akkermansia muciniphila</i> throughout the intestinal sections and feces. We observed persistent increases in acetate and succinate, metabolites <i>A. muciniphila</i><span> is able to produce.</span> Correspondingly, liver H3K4me1 and H3K27 acetylation were enriched around the loci encoding liver cancer-related genes following neonatal BDE-99 exposure. </span></span></span></p> <p class="western"><span><span><span><b>Conclusion. </b><span>Similar to BPA, early life exposure to BDE-99 also produced a cancer-prone hepatic transcriptomic signature corresponding to an increase in permissive epigenetic signatures around cancer-related genes in adulthood. This positively associates with BDE-99 mediated increase in </span><i><span>A. muciniphila</span></i><span> and its metabolites which are established epigenetic modifiers. </span></span></span></span></p>
Radiomics in hepatic metastasis by colorectal cancer
<p>We uploaded the images of the manuscript Granata V, Fusco R, Barretta ML, Picone C, Avallone A, Belli A, Patrone R, Ferrante M, Cozzi D, Grassi R, Grassi R, Izzo F, Petrillo A. Radiomics in hepatic metastasis by colorectal cancer. Infect Agent Cancer. 2021 Jun 2;16(1):39. doi: 10.1186/s13027-021-00379-y. PMID: 34078424; PMCID: PMC8173908.</p>
Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors.
<p>We uploadedthe images of the manuscript "Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors" pubished on European Review for Medical and Pharmacological Sciences 2021.</p>
Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening
<p>We uploaded the image of the mansucript <strong>Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening </strong>accepted on Biology.</p>
Raw Data for the article: Brain magnetic resonance imaging radiomics features associated with hepatic encephalopathy in adult cirrhotic patients
<p><strong>Purpose: </strong>Hepatic encephalopathy (HE) is a potential complication of cirrhosis. Magnetic resonance imaging (MRI) may demonstrate hyperintense T1 signal in the globi pallidi. The purpose of this study was to evaluate the performance of MRI-based radiomic features for diagnosing and grading chronic HE in adult patients affected by cirrhosis.</p> <p><strong>Methods: </strong>Adult patients with and without cirrhosis underwent brain MRI with identical imaging protocol on a 3T scanner. Patients without history of chronic liver disease were the control population. HE grading was based on underlying liver disease, severity of clinical manifestation, and number of encephalopathic episodes. Texture analysis was performed on axial T1-weighted images on bilateral lentiform nuclei at the level of the foramina of Monro. Diagnostic performance of texture analysis for the diagnosis and grading of HE was assessed by calculating the area under the receiver operating characteristics (AUROC) with 95% confidence interval (CI).</p> <p><strong>Results: </strong>The final study population consisted of 124 patients, 70 cirrhotic patients, and 54 non-cirrhotic controls. Thirty-eight patients had history of HE with 22 having an HE grade > 1. The radiomic features predicted the presence of HE with an AUROC of 0.82 (95% CI: 0.73, 0.90; P < .0001; 82% sensitivity, 66% specificity). Radiomic features predicted grade 1 HE (AUROC 0.75; 95% CI: 0.61, 0.89; P < .0001; 94% sensitivity, 60% specificity) and grade ≥ 2 HE (AUROC 0.82; 95% CI: 0.71, 0.93; P < .0001, 95% sensitivity, 57% specificity).</p> <p><strong>Conclusion: </strong>In cirrhotic patients, MR radiomic is effective in predicting the presence of chronic HE and in grading its severity.</p>
Original dataset of the study entitled Effects of trabectedin on the hepatic metabolism of adult zebrafish Danio rerio
<p>Original chromatograms (.qgd files) and normalized peak areas of the annotaded metabolites (.csv file)</p>
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
ClinicalTrials.gov study NCT02118012. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
ClinicalTrials.gov study NCT00742326. IPD Sharing: NO. Countries: 1. Publications: 4.
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
ClinicalTrials.gov study NCT01329978. IPD Sharing: Not stated. Countries: 2. Publications: 2.
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04251715. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
ClinicalTrials.gov study NCT00524173. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
ClinicalTrials.gov study NCT01753557. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
ClinicalTrials.gov study NCT03221309. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
ClinicalTrials.gov study NCT03982186. IPD Sharing: YES. Countries: 19. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.